Aurin tricarboxylic acid, the anti-AIDS compound, prevents the binding of interferon-alpha to its receptor.
Binding of HIV to its receptor, the CD4 molecule of lymphocytes, can be prevented by chemical agents. These agents could be considered as potential anti-AIDS drugs. We have shown that aurin tricarboxylic acid (ATA, 3 microM) specifically blocks the binding of gp120, the HIV coat protein, to the CD4 molecule. We have also found that ATA prevents the binding of interferon-alpha to its receptor in a dose-dependent manner (12-50 microM range). Membrane potential shift, associated with binding of interferon-alpha to its receptor, was also blocked by ATA in a dose-dependent fashion. Our results indicate that potential anti-AIDS drugs should be screened for such undesired side effects.
Gan
Y X
YX
Division of Cytokine Biology and Research, Food and Drug Administration, Bethesda, MD.
Weaver
J L
JL
Pine
P S
PS
Zoon
K C
KC
Aszalos
A
A
D000998:Antiviral Agents / Q000494:pharmacology*; D001312:Aurintricarboxylic Acid / Q000494:pharmacology*; D006678:HIV / Q000187:drug effects; D015699:HIV Envelope Protein gp120 / Q000378:metabolism; D006801:Humans; D007370:Interferon Type I / Q000378:metabolism*; D008564:Membrane Potentials / Q000187:drug effects*; D011948:Receptors, Antigen, T-Cell / Q000378:metabolism; D011971:Receptors, Immunologic / Q000378:metabolism*; D017471:Receptors, Interferon; D014407:Tumor Cells, Cultured
D000998:Antiviral Agents; D015699:HIV Envelope Protein gp120; D007370:Interferon Type I; D011948:Receptors, Antigen, T-Cell; D011971:Receptors, Immunologic; D017471:Receptors, Interferon; D001312:Aurintricarboxylic Acid